Pfizer expands Japan contracting offering touting market knowhow

By Gareth Macdonald contact

- Last updated on GMT

Gettyimages/yu-ji
Gettyimages/yu-ji

Related tags: Pharmacology

Pfizer has expanded its contract manufacturing offering in Japan, adding capacity to make highly potent solid dosage forms at its facility in Nagoya.

The US firm announced the manufacturing expansion last week, adding it has also set up inspection, packaging and testing capacity for both oral solid dosage forms and sterile injectable drugs at the site.

The investment – financial terms of which were not disclosed – is part of an effort to attract drug developers interested in the Japanese market according to Pfizer.

A spokeswoman told us “Japan is the second largest individual pharmaceutical market and many of Pfizer CentreOne’s biopharmaceutical partners are looking to expand into this important market​."

Unique opportunity

However​,” she continued “the Japanese pharmaceutical marketplace is like no other” ​adding the country’s exacting quality and aesthetic standards, pharmacy expectations make it a challenge for manufacturers.

She cited Japan’s ease of use requirements as an example, explaining that to be compliant “the package design itself, not just the label, should help the patient know when and how to take the drug​.”

She added that: “Japan presents a great growth opportunity for small, mid-sized and large biopharmaceutical companies if they can overcome the obstacles for entering the marke​t.”

Global supply

While the Nagoya expansion is focused on helping drug firms tap the Japanese market, the facility will also make drugs for other countries.

The Pfizer spokeswoman told us “Pfizer Nagoya supports the local Japan market but also exports products to Asia Pacific markets.  Nagoya has been inspected by MHLW, PMDA, US FDA, EMA, Korean FDA, ANVISA and AIFA​.”

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Related suppliers

Follow us

Products

View more